CRC Research Update — September 21, 2026
Today's colorectal cancer research highlights
stage-i-ii
A collection of 45 issues
CRC Research Update — September 20, 2026
Today's colorectal cancer research highlights
ctDNA in the Management of Resectable & Advanced Colorectal Cancer
Skip to content
The CRC Digest
◇ RESEARCH
ctDNA in the Management of Resectable & Advanced Colorectal Cancer
A structured narrative review synthesizes evidence on circulating tumor DNA as a biomarker for molecular residual disease after curative-intent treatment, covering tumor-informed and tumor-agnostic assay strategies, postoperative sampling, and serial versus landmark testing
CRC Research Update — September 16, 2026
Today's colorectal cancer research highlights
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
Skip to content
The CRC Digest
◇ RESEARCH
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
A meta-analysis of seven prospective cohorts found that postoperative circulating tumor DNA positivity was associated with increased recurrence risk (pooled hazard ratio, 7.60; 95% CI, 4.70-12.31) after curative-intent colorectal cancer resection,
CRC Research Update — September 08, 2026
Today's colorectal cancer research highlights
Three Distinct Activity Profiles Identified in CRC Survivors Shortly After Treatment
Skip to content
The CRC Digest
◇ RESEARCH
Three Distinct Activity Profiles Identified in CRC Survivors Shortly After Treatment
Accelerometer data from 358 colorectal cancer patients revealed three activity profiles: most sedentary (16%), average (53%), and highly active (31%). (J Cancer Surviv)
This content is informational only and does not constitute
CRC Research Update — September 07, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 31, 2026
Today's colorectal cancer research highlights
Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
Phase III trial shows circulating tumor DNA methylation monitoring can guide postoperative surveillance in nonmetastatic colorectal cancer
The prospective, randomized FIND trial used dynamic ctDNA methylation monitoring to personalize follow-up care after surgery in stage I-III patients. (Journal of Clinical Oncology)
This